Phage-based delivery of CRISPR-associated transposases for targeted bacterial editing
- PMID: 40711918
- PMCID: PMC12318184
- DOI: 10.1073/pnas.2504853122
Phage-based delivery of CRISPR-associated transposases for targeted bacterial editing
Abstract
Phage λ, a well-characterized temperate phage, has been recently leveraged for bacterial genome editing by selectively delivering base editors into targeted bacterial species. We extend this concept by engineering phage λ to deliver CRISPR-guided transposases, accomplishing large insertions and targeted gene disruptions. To achieve this, we engineered phage λ using homologous recombination paired with Cas13a-based counterselection for precise phage modifications. Initially, we established the utility of Cas13a in phage λ by conducting minimal recoding edits, deletions, and insertions. Subsequently, we scaled up the engineering to embed the comprehensive DNA-editing CRISPR-Cas transposase (DART) system within the phage genome, creating λ-DART phages. These modified λ-DART phages were then employed to infect Escherichia coli, generating CRISPR RNA-guided transposition events in the host genome. Applying our engineered λ-DART phages to monocultures and a mixed bacterial community comprising three genera led to efficient, precise, and specific gene knockouts and insertions in the targeted E. coli cells, achieving editing efficiencies surpassing 50% of the population. This research enhances phage-mediated genome editing by enabling efficient in situ gene integrations in bacteria, offering an avenue for further application in microbial community contexts. This scalable method enables flexible microbial genome editing in situ to manipulate the function and composition of diverse ecosystems.
Keywords: CRISPR; Cas; genome editing; phage; transposase.
Conflict of interest statement
Competing interests statement:R.B. is a cofounder of Intellia Therapeutics, Locus Biosciences, TreeCo, CRISPR Biotechnologies and Ancilia Biosciences, and a shareholder of Caribou Biosciences, Inari Ag, Tune Therapeutics, and Eligo Biosciences. J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is an advisor to Vertex, Scribe Therapeutics, Algen Biotechnologies, The Column Group, Inari, Sixth Street, Johnson & Johnson, Altos and Tempus.
Figures
References
-
- Bagarolli R. A., et al. , Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. J. Nutr. Biochem. 50, 16–25 (2017). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
